The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.
 
Chung-Han Lee
Honoraria - Intellisphere
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Calithera Biosciences; Eisai
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
James J Hsieh
Consulting or Advisory Role - BostonGene; Eisai
Research Funding - BostonGene
 
Arpit Rao
Honoraria - Bayer; Cardinal Health; Lilly; Sanofi
Consulting or Advisory Role - Lilly (Inst)
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Pfizer/Astellas (Inst); Seattle Genetics/Astellas (Inst)
 
Alvaro Pinto
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi/Aventis
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Allen Lee Cohn
Honoraria - Amgen
Expert Testimony - Department of Justice
 
Christopher DiSimone
No Relationships to Disclose
 
David R. Shaffer
No Relationships to Disclose
 
Regina Gironés Sarrió
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Pfizer; Roche; Sanofi
Speakers' Bureau - Abbott; Angelini Pharma; Bristol-Myers Squibb; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Abbott; Angelini Pharma; Pfizer; Roche; Sanofi
 
Sara Gunnestad Ribe
Stock and Other Ownership Interests - Nordic Nanovector
 
Jane Wu
Employment - Eisai
 
Emmett V. Schmidt
Employment - Merck Sharp & Dohme
 
Peter Kubiak
Employment - Eisai
Stock and Other Ownership Interests - Apex; ImmunoGen; Mallinckrodt; Seres Therapeutics; Sesen Bio; ZIOPHARM Oncology
 
Chinyere Okpara
Employment - Eisai Europe
 
Alan D. Smith
Employment - Eisai Europe
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb